What Bronchoretard mite Treats: Main Uses and Benefits

This medication is generally considered relevant for the management of chronic respiratory diseases. The active component, a xanthine derivative, is relevant in contexts involving heightened systemic burden, as applied across domains where additional symptomatic support is needed.

---

Long-Term Management of Chronic Airway Conditions

It is applied in managing conditions involving episodic or fluctuating manifestations, including bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD). The medication is used to address the persistent symptoms associated with these ongoing conditions, which helps maintain a sense of stability when symptoms are more noticeable.

---

Easing Symptoms of Wheezing and Chest Tightness

The drug offers symptomatic relief by targeting symptoms related to physical discomfort, such as frequent wheezing and the uncomfortable feeling of chest tightness. Its supportive benefit assists with maintaining functional stability, which contributes to easing the overall symptom load. This is relevant for managing symptoms that interfere with daily comfort.

---

Role in Prophylactic Symptom Control

The sustained-release nature means it is often incorporated into a daily regimen to provide prophylactic support, and may assist with managing symptoms that become more disruptive during flare-ups. This long-term, continuous approach is considered relevant when additional symptomatic support is needed for chronic airflow limitation.

Quick Fact

Quick Fact: Relief for Airway Constriction

This medication is applied in managing symptoms like wheezing and chest tightness that arise from the narrowing of the airways, thereby supporting easier breathing.

Official Population Eligibility for Bronchoretard mite (Choline Theophyllinate)

Official regulatory documents define strict criteria for who can and cannot use this medicine, focusing on age, underlying medical conditions, and hypersensitivity. The active ingredient, Choline Theophyllinate, is a xanthine derivative, and its use is subject to restrictions based on drug clearance and toxicity risk.

Who Must Not Use the Medicine (Contraindications)

• Use is absolutely contraindicated in patients with a known hypersensitivity or allergy to Theophylline, Choline Theophyllinate, or any other related xanthine derivatives.
• The prolonged-release tablet formulation is generally not recommended for children under six years of age.

Populations Requiring Conditional Use (Use with Caution)

Use with caution and dose adjustment is explicitly required for patients with conditions that reduce the drug's clearance, increasing the risk of accumulation and toxicity. These include:

• Organ and Heart Function: Patients with severe hepatic impairment (liver disease), Congestive Heart Failure (CHF), or Cor Pulmonale.
• Other Conditions: Individuals with active peptic ulcer disease, seizure disorders, or those experiencing sustained high fever (e.g., due to sepsis).
• Age and Status: The elderly (over 60 years) and individuals who have recently changed their smoking status (started or stopped) require close monitoring.

Pregnancy and Lactation Eligibility

The medicine is not recommended during pregnancy unless deemed essential by a physician. It is secreted into breast milk, and conditional use requires monitoring the infant for potential signs of toxicity.

Interactions with other medicines and products

Interactions with Bronchoretard mite (Choline Theophyllinate/Theophylline) are primarily governed by the active substance's narrow therapeutic index and its metabolism via the Cytochrome P450 1A2 (CYP1A2) enzyme. Changes in the activity of this enzyme due to co-administered substances can significantly alter the body's exposure to the drug.

Pharmacokinetic and Pharmacodynamic Interactions

Officially documented interactions fall into two main categories:

• Increased Exposure: Medicines that inhibit the CYP1A2 enzyme, such as the antibiotics Ciprofloxacin and Erythromycin, and agents like Cimetidine or Allopurinol, decrease the clearance of Theophylline. This mechanism formally results in an increase in the serum concentration of the active substance, raising the risk of accumulation.

• Decreased Exposure: Substances that induce the CYP1A2 enzyme, notably Tobacco Smoke and certain antiepileptics like Phenytoin or Phenobarbital, accelerate the clearance of Theophylline. This formally results in decreased serum concentration and potential loss of the drug's intended effect.

Restrictions and Other Substances

Co-administration with other xanthine-containing preparations is strictly prohibited due to the risk of additive stimulant effects. The potent CYP1A2 inhibitor Fluvoxamine is also a contraindicated combination. Furthermore, the drug exhibits a pharmacodynamic interaction with Adenosine, where Theophylline can act as an antagonist. Consistent timing relative to meals is required for specific sustained-release forms to prevent absorption-related issues.

How Bronchoretard mite Works: Understanding the Mechanism of Action

Bronchoretard mite, whose active ingredient is theophylline, acts through multiple complementary molecular pathways to influence cellular signaling processes in the airways.

---

Dual Modulation of Signaling Pathways

Bronchoretard mite engages mechanisms that influence overactive or dysregulated processes, primarily by acting as a non-selective phosphodiesterase (PDE) inhibitor and a non-selective adenosine receptor antagonist. Inhibition of PDE prevents the hydrolysis of cyclic AMP (cAMP) within smooth muscle cells, while the antagonism of adenosine receptors blocks the effects mediated by adenosine signaling. This dual action modifies early molecular steps that shape systemic physiological consequences.

---

Cascade of Bronchodilatory Effects

The increase in intracellular cAMP concentration, facilitated by PDE inhibition, initiates signaling sequences that lead to downstream effects. Elevated cAMP activates Protein Kinase A, which in turn promotes changes within bronchial smooth muscle cells. This modification supports a more regulated state within the targeted pathways, and results in the physiological consequence of bronchodilation (airway smooth muscle relaxation).

---

Anti-inflammatory Pathway Adjustment

The drug modulates key pathways associated with cellular inflammatory processes by influencing gene transcription. It functions as a histone deacetylase 2 (HDAC2) activator, an action that suppresses the transcription of pro-inflammatory genes, such as those regulated by the transcription factor NF-κB. This cascade influences the regulation of processes driven by distinct signaling patterns and reducing the transcriptional activity of pro-inflammatory mediators.

Official Administration Guidelines

"Bronchoretard mite" is an oral medication whose usage is precisely structured to maintain stable concentrations of the active substance, a xanthine derivative. The official regimen is based on the drug's specialized sustained-release formulation, designed for chronic, long-term administration, and is not intended for the relief of acute episodes.

The medication is taken daily, either once a day or in divided doses (typically every 12 hours), a schedule that leverages the extended-release mechanism to support consistent therapeutic levels. Adult dosing regimens are individualized and guided by monitoring the concentration of the drug in the blood. A typical starting dosage for theophylline is 300 mg to 400 mg daily, which may be titrated to a maintenance range of 400 mg to 600 mg per day, with the maximum recommended dosage generally not exceeding 600 mg daily.

A critical administration instruction is that the sustained-release tablet must be swallowed whole. Crushing, cutting, or chewing the tablet is strictly forbidden, as this action bypasses the controlled-release feature and results in a rapid release of the entire dose. The tablet may be administered with or without food, though administration should be consistent from day to day.

Specific dose adjustments are required for certain populations. For older adults (over 60 years), the maximum daily dose is typically limited to 400 mg due to altered clearance rates. Patients with documented hepatic impairment also require dose reduction or extended intervals. Dosing adjustments are made incrementally, often in steps no sooner than every three days, and are guided by therapeutic drug monitoring to ensure appropriate blood levels.

Evidence Overview for Chronic Conditions

Research exploring the active substance, Choline Theophyllinate, was studied for chronic bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) through Randomized Controlled Trials (RCTs) and systematic reviews. For chronic asthma, studies monitored outcomes related to physical discomfort, including lung function and patient-reported changes in nocturnal symptoms, primarily in stable adults and children. In the context of COPD, research examined long-term outcomes such as documented monitoring of episodic or acute changes (exacerbation rates) and patient-reported quality of life. The evidence for both chronic applications is generally classified as Moderate by regulatory reviewers, reflecting its established role as part of this pharmacological class.

Research on Physiological Action and Limitations

Pharmacodynamic (PD) studies and physiological Comparative Trials have explored the direct physiological response related to airway dilation by measuring objective spirometric values. The evidence base research describes this physiological action described in studies, which is associated with a level of evidence described as High for this basic understanding. However, the evidence for clinical use in specific groups remains limited. Research was evaluated in specific cohorts of children with chronic asthma and older adults, but data for certain groups remain insufficient. Many key studies are historical, meaning sample sizes were modest, and the overall picture on durability of response and long-term effects are not fully established. This evidence contributes to understanding symptom patterns, but research does not determine whether an individual will respond similarly.

Common questions about Bronchoretard mite (FAQ)

Q: What is the active ingredient in Bronchoretard mite?

According to the official product information, the active substance contained in this medicine is theophylline. Theophylline is the ingredient indicated for its bronchodilator effect.

Q: Can I crush or chew the tablets?

Regulatory documents indicate that Bronchoretard mite tablets should be swallowed whole. This is because the medication is designed to be slow-release, meaning the active substance is slowly delivered to the body over time. Altering the tablet would interfere with this release mechanism.

Q: How should I store Bronchoretard mite?

Official information indicates the medication should be stored below 25 C. It should be kept in the original packaging. Storing it this way helps protect the tablets from excessive light and moisture, as recommended by the manufacturer.

Q: Is it safe to drive after taking this medicine?

Studies and official information indicate that this medicine may slightly affect reaction time, particularly when treatment is first started. The product information advises caution regarding driving and operating machinery.

How to Store and Dispose of Bronchoretard mite?

The storage and disposal of Bronchoretard mite (Choline Theophyllinate sustained-release tablets) must strictly adhere to the conditions mandated by official regulatory labeling to ensure product stability.

Official Storage Requirements

Condition	Regulatory Mandate
Temperature	Store at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF). Do not freeze.
Protection	Protect from moisture and protect from light. Keep the tablets in their original, tightly closed container until use.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Bronchoretard mite must not be disposed of in household trash or poured down the sink or toilet. Official guidance requires returning the medication to a drug take-back program or disposing of it as per local pharmaceutical waste regulations.